Mixed lineage leukemia (MLL) gene
rearrangements are associated
with acute leukemia. The protein menin is regarded as a critical oncogenic
cofactor of the resulting MLL fusion proteins in acute leukemia. A
direct interaction between menin and the MLL amino terminal sequences
is necessary for MLL fusion protein-mediated leukemogenesis. Thus,
inhibition of the interaction between menin and MLL has emerged as
a novel therapeutic strategy. Recent improvements in structural biology
and chemical reactivity have promoted the design and development of
selective and potent menin–MLL interaction inhibitors. In this
Perspective, different classes of menin–MLL interaction inhibitors
are comprehensively summarized. Further research potential, challenges,
and opportunities in the field are also discussed.
Introduction of the N,N-dimethylaminoethoxy
group to pyrido[3,2-d]pyrimidine led to the discovery
of menin–mixed lineage leukemia (MLL) interaction inhibitor C20. C20 showed strong binding affinity to menin
protein and achieved sub-micromolar potency in cell growth inhibition. C20 had good selectivity for the inhibition of the interaction
between menin and MLL in the kinase profile evaluation. Pharmacokinetic
studies demonstrated that C20 possessed good stability
and low clearance rate in liver microsomes and acceptable bioavailability
in rats. Subsequent oral administration of C20 showed
potent antitumor activity in the MV4;11 subcutaneous xenograft models
of MLL-rearranged leukemia. The docking study showed that C20 bound highly with menin, and the N,N-dimethylaminoethoxy group occupied the F9 pocket of menin. This
study proved that introducing a hydrophilic group into the F9 pocket
of menin would be a new strategy for the design of menin–MLL
interaction inhibitors with potent binding affinity and improved physical
properties.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.